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Introduction. This article reviews current management strategies for DCIS in the context of recent randomised trials, including
the role of sentinel lymph node biopsy (SLNB), adjuvant radiotherapy (RT) and endocrine treatment. Methods. Literature
review facilitated by Medline, PubMed, Embase and Cochrane databases. Results. DCIS should be managed in the context of a
multidisciplinary team. Local control depends upon clear surgical margins (at least 2mm is generally acceptable). SLNB is not
routine, but can be considered in patients undergoing mastectomy (Mx) with risk factors for occult invasion. RT following BCS
signiﬁcantly reduces local recurrence (LR), particularly in those at high-risk. There remains a lack of level-1 evidence supporting
omissionofadjuvantRTinselectedlow-riskcases.Large,multi-centricorrecurrentlesionsshouldbetreatedbyMxandimmediate
reconstruction should be discussed. Adjuvant hormonal treatment may reduce the risk of LR in selected cases with hormone
sensitive disease. Conclusion. Further research is required to determine the role of new RT regimes and endocrine therapies.
Biological proﬁling and molecular analysis represent an opportunity to improve our understanding of tumour biology in DCIS to
rationalise treatment. Reliable identiﬁcation of low-risk lesions could allow treatment to be less radical.
1.Introduction
1.1.Diagnosis. Theintroductionofnationalmammographic
screening programmes and the increasing use of digital
mammography and MRI have dramatically changed the
clinical presentation of DCIS. Prior to this, DCIS made
up a small proportion of all breast malignancy and was
only diagnosed in patients presenting with a palpable mass,
pathological nipple discharge, or occasionally found as an
incidental biopsy ﬁnding [1, 2]. In contrast, it is now most
frequently identiﬁed in asymptomatic women with screen-
detected micro calciﬁcations [3]a n dm a k e su pal a r g e r
proportion of breast malignancy. Approximately one ﬁfth of
all screen-detected breast cancers are now DCIS [4].
Although the rates of all breast malignancy have
increased with time, between 1980 and 1995, Western
countries have experienced a four-fold “increase” in the
incidence of DCIS speciﬁcally, particularly in women of
screening age [5].
Data froma systematic reviewof 374 studies reported the
pooled incidence of DCIS in the early 1970s as 5.8/100000
and this had risen to 32.5/100000 in 2004 [6]. A higher
proportion of the cases post screening were non comedo
DCIS, which is considered less aggressive.
Screening and cancer registry data from Norway includ-
ing 2.3 million women reported in 2010 showed an increase
in incidence of DCIS from 4/100000 before the introduction
of screening to 11/100000 postintroduction. In women of
screening age, the proportion of DCIS within breast malig-
nancy rose from 5% to 13%. Age-standardised rates of all
breast cancer including DCIS increased over time in those of
screening age, but a large peak at the point screening was
introduced, subsequent drop in incidence (but not to pre-
screening levels), then a steady climb over time. Rates were
also higher in prevalent as opposed to incident screens [7].
These studies seem to suggest that the introduction of
screening is largely responsible for the apparent increased
incidence of DCIS in recent times, but that the stage of
the disease may be much earlier and possibly less clinically
relevant [6].
The trend is likely to continue with further technological
advances, including the transition from analogue to full-
ﬁeld digital mammography (FFDM) and the development of
computer-aided detection (CAD) [8].2 International Journal of Surgical Oncology
Figure 1: MRI appearance of recurrent DCIS.
Although the role of MRI in the management of DCIS
is yet to be fully evaluated by randomised trials, it is being
usedtoassessdiseaseextentanddistributionandtoassessthe
contralateral breast [9, 10]. It is also used for early detection
ofinvasiveandnoninvasivebreastcancerinhigh-riskwomen
[11]. A recent prospective observational study demonstrated
MRI to be signiﬁcantly more sensitive than mammography
for the diagnosis of DCIS (92% versus 56%) [12].
MRI can overinterpret nonmalignant incidental lesions
which may result in unnecessary interventions [13]. A recent
retrospective report looking at MRI screening of high-risk
women demonstrated an increased sensitivity of MRI for
DCIS that was at least as good as the sensitivity for invasive
disease [14]. This study examined two time periods (before
2001; 223 women and after 2001; 391 women) in one unit
which used MRI and mammography to screen high-risk
patients. After 2001, the unit acquired additional breast
coils, better methods of data processing, and staﬀ with
appropriate specialist training. In the ﬁrst period, 3.1% of
screens were positive and 13% of these were DCIS. All were
diagnosed by mammography. In the second period, 3.3%
of screens were positive, 34% were DCIS. All of these were
diagnosed by MRI and just one of these was also seen
on mammography. The speciﬁcity of MRI was lower than
mammography and signiﬁcantly more patients were recalled
for suspicious changes on MRI in the second study period
than the ﬁrst, but there was no signiﬁcant diﬀerence in the
numbers of biopsies performed.
Figure 1 shows regional ductal enhancement in the UOQ
of the left breast anterior to a lumpectomy site in a 49-year-
old female. This was recurrence picked up on screening MRI.
Her mammogram was normal.
Mammary ductoscopy has been used to directly visu-
alise DCIS. Figure 2 shows the appearance at mammary
ductoscopy of histologically veriﬁed DCIS. However, this
technique requires further investigation [15]. For example,
it is limited by the fact that not all ducts are accessible from
the nipple [16].
Currently, the preoperative diagnosis of impalpable
lesionssuspiciousofDCISrequireseitherstereotacticorMRI
guidedcorebiopsy.Vacuum-assistedcorebiopsy(VACB)has
been shown to increase the diagnostic yield and upgrade
Figure 2: Appearances at mammary ductoscopy of DCIS.
atypical ductal hyperplasia (ADH) to DCIS in approximately
25% of cases [17] and can be employed where standard core
biopsy does not show DCIS yet the radiological changes are
suspicious.
2. Pathological andClinicalCorrelation
2.1. Classiﬁcation. DCIS is deﬁned by two features: ﬁrstly,
the malignant epithelial proliferation is limited by the
ductal basement membrane and secondly, stromal invasion
is absent. DCIS behaves as a nonobligate precursor of
invasive carcinoma and does not fully express the malignant
phenotype [1]. The progression to invasive breast cancer is
not completely understood and cannot be reliably predicted.
Classiﬁcation systems aim to reproducibly categorise lesions
and to provide prognostic information to aid management
decisions.
DCIS may be classiﬁed by grade, by architecture or
morphology, by the level of diﬀerentiation, or by systems
which use a combination of these factors [18].
Conventional histopathological types include comedo
(tending to high grade cellular/nuclear features, often with
central necrosis and calciﬁcation), solid, cribriform (with
small holes or open spaces), and micropapillary (ﬁnger-like
projections), however, lesions often demonstrate architec-
tural and morphological heterogeneity [19, 20].
Cytonuclear grade is conventionally deﬁned as low,
intermediate, or high. It may vary between pathologists [21]
and protocols have been developed to standardise reporting
of grade [22].Figures3and4showthecharacteristicfeatures
of low- and high-grade DCIS.
The “Comedo” subtype (high-grade, central conﬂuent
necrosis, and solid architectural pattern in >50% of the duct
spaces)andthepresenceorabsenceofnecrosisareimportant
features and are incorporated into classiﬁcations such as the
Van Nuys Index [23] and the Nottingham Grade [24].
All of the above classiﬁcation methods as well as tumour
size and the presence of absence of inﬂammatory changesInternational Journal of Surgical Oncology 3
Figure 3: Low-grade DCIS.
have been found to be statistically associated with the risk
of local recurrence in an independent pathological review of
casesfromtheUKCCCR/ANZDCIStrial[18].Thisindicates
their independent value in the classiﬁcation of DCIS. Their
combination and weight in terms of prognosis is yet to be
deﬁned.
2.2. Natural History. T h ee l u s i v en a t u r a lh i s t o r yo fD C I S
probably reﬂects the biodiversity of the condition. Preinva-
sive lesions donotinvariably progress toinvasive malignancy
[25].
The natural history of small, noncomedo, low-grade
DCIS treated by biopsy alone has been evaluated in long-
term followup studies. After a median of thirty-one years,
39%ofpatientsdevelopedinvasivebreastcancer,allofwhich
occurred in the index quadrant and 45% of these patients
died of metastatic disease [26]. The overall progression to
invasive breast cancer has been reported to range from 14%
to 75% [27].
There is a wide body of evidence on the risk factors
for breast cancer overall, but evidence on risk factors
speciﬁc to DCIS is limited. However, it does appear that
the same factors are involved as for invasive disease; high
mammographic density, signiﬁcant family history of breast-
cancer, age, obesity, and high lifetime exposure to oestrogens
[11].
Hence, it would seem that patients who receive no
treatment beyond a diagnostic biopsy remain at signiﬁcant
risk of progression to invasive disease and that DCIS
represents a precursor of invasive cancer. Increased risk has
been demonstrated in lesions of all nuclear grade. On the
other hand, a signiﬁcant proportion of DCIS lesions do not
progress.Asdiagnosticfrequencycontinuestoincrease,there
is an impetus to accurately identify clinically relevant lesions
in order to rationalise management.
2.3.ClinicalCharacteristics. WomenwithpalpableDCISand
those who present symptomatically exhibit higher rates of
LR than mammographically detected cases [28, 29]. Some
screen-detected lesions may, therefore, be less relevant than
symptomatic lesions [30].
Figure 4: High-grade DCIS.
One study identiﬁed a family history of invasive breast
cancer as a signiﬁcant predictor of LR in women with
DCIS treated with BCS and RT [31]. Previous therapy with
oestrogens, either contraceptives or hormone replacement
therapy, is also reported to be a signiﬁcant predictor of LR
[32].
Young age (<40 years) has emerged as an independent
riskfactorforLRafterBCSwithorwithoutadjuvantRT[33].
LR has been reported to range from 11–31% in this group,
with the lowest rates in mammographically detected lesions
[33].
2.4. Pathological Characteristics. A meta-analysis of 44 trials
has reported signiﬁcantly increased pooled risk estimates for
local recurrence after treatment for DCIS if the disease is
classiﬁedas“comedo”type,multifocal,ifthelesionislargeor
highgrade.Involvedmarginswereassociatedwiththehighest
increase in risk estimates and there was limited evidence that
ER- and PR-positive HER2 negative disease is less likely to
recur [34].
In the meta-analysis, the pooled risk estimates for size
were derived from 7097 women. Lesions greater than 20mm
in size were compared with lesions less than 20mm. The
risk estimate for larger lesions was 1.63 (95% CI 1.30–
2.06). Accurate and reliable measurement of DCIS can be
challengingandseverallandmarkstudieshavebeencriticised
for their performance in this regard [29, 35, 36]. The large
numbers in the meta-analysis will have helped to mitigate
this factor. The same study reported the summary risk
estimate for multifocal versus unifocal disease to be 1.95
(95% CI 1.59–2.40) from analysis of 3895 patients [34]. It
is possible that the total area of DCIS in multifocal lesions is
greater than unifocal disease and that the diﬀerence in local
recurrence could be secondary to this.
Involved margins are associated with an increase in LR,
in patients treated by BCS alone, and in those who also
undergo RT [37–39] .C o n s e n s u sh a sy e tt ob er e a c h e dw i t h
regard to optimal margin width [36] .T h ep r e s e n c eo fD C I S
at the surgical margin is associated with the identiﬁcation
of residual DCIS in 40–82% of reexcision specimens, and
is correlated with margin width: 41% at <1mm, 31% at 1-
2mm and 0% with ≥2mm of clearance [40]. The French
NationalGuidelinesrecommendsurgicalmarginsof ≥3mm,4 International Journal of Surgical Oncology
and reexcision for margins <1mm [41]. A meta-analysis
reporting the eﬀect of margin status on local recurrence after
BCS and RT concluded that a margin width of ≥2mmwas
signiﬁcantly superior to lesser margins (odds ratio (OR) =
0.53, 95% CI 0.26–0.96). However, there was no added value
associatedwithclearance ≥2mmcomparedto>5mm(OR=
1.51, 95% CI 0.51–5.0) [42]. Despite this, total excision
volume, independent of margin clearance, has also been
correlatedwithLR.FollowingBCSforDCIS,theJointCentre
E x p e r i e n c er e p o r t e dL Rr a t e sa t5y e a r so f9 %a n d0 %f o r
volumes <60cm3,a n d>60cm3 respectively [43]. Excision
volumes <60cm3 have been shown to increase the relative
risk of LR in women under 45 years [33]. Margins were
associated with the largest diﬀerence in the risk estimates
for local recurrence in the meta-analysis by Wang [34]. The
summaryriskestimateforwomenwithinvolvedmarginswas
2.25 (95% CI 1.77–2.86).
High nuclear grade is associated with a greater risk of LR.
In Wang’s meta-analysis [34], 10,526 women were included
in the analyses relating to grade, the summary risk estimate
for high grade versus non-high-grade disease was 1.81 (95%
CI 1.53–2.13).
Thecombinationofnucleargradeandcomedonecrosisis
strongly associated with the risk of LR after BCS [23]. In the
same meta-analysis of 9332 womenwith DCIS, the summary
risk estimate of comedo-necrosis versus none for invasive
breast-cancer recurrence was 1.71 (95% CI 1.36–2.16) [34].
A recent population-based case-control study found that
comedo-type DCIS shares a similar proﬁle of hormonal
and reproductive risk factors to IBC, including ≥10 years
of oral contraceptive intake and an inverse association with
≥3 full-term pregnancies. These ﬁndings were in contrast
to those for noncomedo lesions, providing some further
support for the diﬀerential management of DCIS lesions
[44]. The signiﬁcance of comedo-type as a risk factor for LR
has resulted in its inclusion in prognostic indices [45, 46].
H i g h - g r a d eD C I Sw h i c hi so e s t r o g e nr e c e p t o r( E R )
and progesterone receptor (PR) negative is signiﬁcantly
associated with HER2 and p53 positivity [47]. HER2 posi-
tivity and ER/PR negativity are individually associated with
increased risk of LR [48]. HER2 overexpression represents
an aggressive biological subtype of DCIS, correlating with
highgrade,p53expression,andhormonereceptornegativity.
Hormone receptor positivity has been associated with low-
grade DCIS. In a recent case series, HER2 was found to
be superior to lesion size or nuclear grade in predicting
concurrent invasive disease. DCIS that overexpressed HER2
was 6 times more likely to be associated with invasive disease
(OR 6.4, P = 0.01) [49].
In the Wang meta-analysis [34], higher rates of local
recurrence were seen in ER/PR negative, HER2, positive-
patients but the diﬀerences were not statistically signiﬁcant.
2.5. Molecular Characteristics. Various molecular markers
have been studied in DCIS as possible predictive or prognos-
tic factors for progression to invasion or for the development
of invasive recurrences.
In invasive breast cancer, classiﬁcations based on bio-
logical proﬁle (derived from gene proﬁling and correlated
with immunohistochemical proﬁle) rather than morphology
have been developed and shown to correlate with prognosis.
In order; Luminal A, Luminal B, Triple negative, and Basal
Type invasive breast cancers are associated with a worsening
prognosis [50] .T h es a m ep r o ﬁ l e sh a v ebe e nd e m o n s tra t e di n
DCIS [51]. More work is now needed to establish whether
these proﬁles inﬂuence the likelihood that an area of DCIS
will progress.
Chromosome-wide comparative genomic hybridization
has shown DCIS to be a genetically advanced lesion with
alterations corresponding to adjacent invasive disease and
independentpathwaysofgeneticevolution[52].Adistinctive
molecular portrait of each lesion can be obtained by gene
expression proﬁling using complementary DNA micro-
arrays [53].
One such study has identiﬁed a gene expression classiﬁer
of 35 genes which diﬀer between DCIS and IBC and a
further 43 genes distinguishing well-from poorly diﬀerenti-
ated DCIS [54]. Protein expression proﬁling can similarly be
undertakenusingmatrix-assistedlaserdesorption/ionization
(MALDI) or surface-enhanced laser desorption/ionization
(SELDI). Although the relevance of each parameter may not
befullyunderstood,combinationsoffeaturesmayenablethe
biological proﬁling of DCIS lesions into groups of similar
natural history and prognosis.
Balleine et al. recently reported on a binary molecular
grading scheme for DCIS, based on expression at 173 oligo-
nucleotide probes. Two conventional parameters amenable
to routine evaluation (nuclear grade and Ki67 score) were
capable of accurately assigning lesions into low or high
molecular grade [55].
Proteomics analysis of DCIS and normal breast tissue
has also identiﬁed diﬀerential expression patterns, distinct
from previous nucleic-acid-based studies [56]. Expression
of Syndecan-1, E-cadherin, and c-met have recently been
shown to be associated with angiogenic and lymphan-
giogenic factors in DCIS, including endothelin A and B
receptors, vascular endothelial growth factor (VEGF)-A/C,
and ﬁbroblast growth factor receptor (FGFR)-1 [57]. In
addition to their potential use for prognostication, putative
molecular targets may enable directed therapy in the future.
Intuitively, molecules such as matrix-metalloproteinases
(MMPs) and tissue inhibitors of matrix-metalloproteinases
(TIMPs) that inﬂuence the invasion of stroma and basement
membrane should be important in the progression of DCIS
to invasive breast cancer. Signiﬁcantly diﬀerent expression
p r o ﬁ l e so fM M P sa n dT I M P sh a v eb e e nn o t e di nD C I S ,
admixed DCIS, and invasive breast cancer [58]. More work
is needed to understand the role these molecules have in
progression to invasive cancer but their expression proﬁles
could help determine lesions that should be treated more
aggressively.
3. Management
ItispossiblethatnotallDCISneedstobetreatedaggressively
as not all DCIS will become invasive. In particular, small,International Journal of Surgical Oncology 5
low-grade lesions detected by screening may ﬁt into this
group. Management strategies need to consider the breast
and axilla, the need for adjuvant RT, and the role of systemic
adjuvant therapy. Treatment of the breast can involve BCS
(with or without RT) or mastectomy (Mx). Axillary surgery,
even SLNB, warrants particular caution in view of their low
yield and potential for harm. Adjuvant systemic treatments
have mainly involved oestrogen blockade with Tamoxifen.
The optimal management of DCIS remains controversial
[59].
3.1. Surgery. Complete excision of DCIS with clear margins
is the most important factor in reducing the risk of LR.
Mx is indicated for large tumours (>4cm depending on
breast size), multicentric lesions, inadequate margins after
BCS, local recurrence after BCS (particularly with prior RT),
and patient preference. Mx aﬀords excellent local control,
approximately 98% at 7 years, with an overall recurrence rate
of 1.5% [60].
In England and Wales between 1990 and 2001, the
absolutenumberofmastectomiesforinsitudiseaseincreased
by 400%, corresponding to the introduction of national
screening [61]. The relative rate of Mx for DCIS has been
decreasing over the last three decades and the procedure is
now undertaken in approximately one third of patients [62].
The French Survey reported Mx rates of 10% for lesions
<10mm compared to 72% for >20mm, and 11% for low-
grade compared to 54% for high-grade lesions. The authors
justify an Mx rate of 50% for patients <40 years by the
lifetime risk of LR in those undergoing BCS despite adjuvant
RT [62].
If patients do require Mx for DCIS, an immediate breast
reconstruction is relatively uncomplicated as postmastec-
tomy radiotherapy and lymph node dissection will not be
required [63].
BCScombinedwithRTisanacceptabletreatmentoption
for smaller, unifocal areas of DCIS. There is probably not
enough evidence to justify BCS without RT routinely. Sig-
niﬁcant numbers of patients undergoing BCS alone develop
LR, of which approximately half are invasive and up to one
ﬁfth ultimately metastatic. The literature reveals an overall
LR rate of approximately 28% at 7 years, around 45% of
whichareinvasive[37–39,64–68].Thereisalsoevidencethat
mammographically detected DCIS treated by BCS alone has
unacceptable rates of LR (10-year LR rates were 27.8%, 22%,
and 19%, resp., of which approximately 35% were invasive)
[68–70].
3.2. Radiotherapy. T h eb e n e ﬁ to fa d j u v a n tR T ,i nt e r m so f
reducedLRinthoseundergoingBCS,hasbeendemonstrated
by several large randomized controlled trials. However, clear
marginsarenecessaryevenifRTisgiventoobtain acceptable
r a t e so fL R[ 37, 38, 71, 72]. There remains a lack of level-1
evidence supporting the omission of adjuvant RT in selected
low-risk cases.
The National Surgical Breast and Bowel Project (NSABP
B-17) trail randomized 818 patients after BCS surgery for
DCIS,toeitherwholebreastRTornofurthertreatment[35].
After a median followup of 129-months, of the 403 women
treated by wide local excision alone, there were 124 local
recurrences (31.7%), 67 of which were invasive (54%). Of
the410womentreatedbywidelocalexcisionandRT,61local
recurrenceswereobserved(15.7%)ofwhich29wereinvasive
(48%, P = 0.001). Despite the fact that RT was associated
with a 57% reduction in LR (both invasive and in situ), no
diﬀerences were observed in the rates of distant recurrence
and overall survival.
An analysis of long-term data from the NSABP B-17
and NSABP B-24 trials [73] showed that at 15 years the
radiotherapy treated patients still had signiﬁcantly fewer
local recurrences and this eﬀect had increased over time.
Of those that did recur, 54% were invasive, and for these
patients, overall survival was lower (HR of death = 1.75, 95%
CI = 1.45 to 2.96, P<0.001).
The European Organisation for Research and Treatment
of Cancer (EORTC) conducted a similar study recruiting
1010 patients [29]. After a median followup of 126 months,
local relapse-free rates were 85% in the RT group and 74%
in the control group (HR: 0.53, P<0.0001). In situ LR rates
were 7% and 13%, respectively, and invasive LR rates were
8% and 13% respectively [74]. Consistent with the NSABP
B-17 trial ﬁndings, the absolute reduction of LR by RT
increased with time from 7% at 4 years to 11% at 10.5 years.
In univariate analysis, RT showed a statistically signiﬁcant
beneﬁtinallsubgroupsofpatients,butthesizeofthisbeneﬁt
varied. The authors observed a 23.5% and 42.7% LR rate for
complete and incomplete/doubtful excisions, respectively, in
the lumpectomy alone group, versus 14.7% and 24.7% for
patients receiving adjuvant RT. Indicating the importance of
clear margins even with RT.
The UK/ANZ DCIS trial involved 1701 patients treated
by BCS, with subsequent randomisation to RT and/or
Tamoxifen [75]. There were four treatment groups: BCS
alone,BCS+RT,BCS+TAM,andBCS+ RT+ TAM.90%of
the participants were 50 years or older with screen detected
DCIS. After a median followup of 53 months, the respective
rates of LR were 22%, 8%, 18%, and 6%. Adjuvant RT
was associated with a signiﬁcant reduction (hazard ratio
(HR)= 0.38, P<0.0001) in all ipsilateral tumour recurrence
(invasive or DCIS). RT reduced the risk of DCIS by 64%
(P = 0.0004) and invasive cancer by 55% (P = 0.01). Long-
term followup data has since been reported for this trial [76].
At a median followup of 12.7 years, the treatment eﬀects are
similar in magnitude.
The Cochrane Collaboration has recently published a
systematic review of four adjuvant RT trials: NSABP 2001
[35], EORTC 2006 [29], UK/ANZ DCIS 2003 [75] and the
Swedish DCIS 2008 [77]. With regard to LR, they report a
51% pooled risk reduction for DCIS (HR 0.61, 95% CI 0.39–
0.95, P = 0.03) or invasive cancer (HR 0.50, 95% CI 0.32–
0.76, P = 0.001). After a median followup ranging from
4.4–10.5 years, the LR rate for those receiving RT was 11.6%
compared to 23.9% for BCS alone, resulting in a number
needed to treat (NNT) of 9 patients to prevent one LR.
Although there was no attributable increase in mortality,
long-term RT complications were poorly reported by the
trialists [78].6 International Journal of Surgical Oncology
A further meta-analysis also concluded that adjuvant
RT signiﬁcantly reduces the risk of LR after BCS—by
approximately 60%, with most beneﬁt to patients with high-
grade lesions and positive margins. RT did not signiﬁcantly
alter the rate of distant metastases or overall survival [79].
O v e r a l l ,L Rr a t e sh a v eb e e nr e p o r t e dt or a n g ef r o m
2.7% to 18.9%, averaging 10% at 7 years, with invasive
LR accounting for approximately 60% [80]. However, the
methodological quality of several trials has been criticised,
particularly in terms of the treatment of unclear margins,
the methodology and design of the studies, and the validity
of conducting posthoc secondary retrospective analyses [29,
35]. Whilst some of these issues can be resolved by meta-
analysis, others are being addressed by current studies.
Although it has been long been proven that radiotherapy
after mastectomy for invasive breast-cancer reduces local
recurrence [81], good evidence that this in turn leads to
reducedmortalitytookmuchlongertobepublished[82,83].
DCIS is associated with a better prognosis than invasive
breast cancer and, therefore, proof of a survival beneﬁt with
radiotherapy may take time to establish.
Strategies such as a boost of RT to the tumour bed are
used in IBC. There is no evidence that this reduces LR in
DCIS. A study of 75 patients treated by BCS+RT, including
20 women receiving an additional 10Gy boost to the tumour
bed, identiﬁed no improvement in LR reduction after a
median followup of 81months [84]. The eﬃcacy of other
novel strategies including partial breast RT in the context
of DCIS has yet to be evaluated [71, 72, 85]. Accelerated
partial breast irradiation (APBI) aims to provide comparable
local control to whole-breast RT with reduced morbidity. In
the largest study group of patients with DCIS (n = 194)
treated with the MammoSite device, the 3-year actuarial
LR rate was 0% in the ﬁrst 48 cases enrolled compared to
2.04% in IBC (n = 352); median followup 37.5 months [86].
Another recent study of 126 DCIS cases evaluated balloon-
based brachy therapy, with either MammoSite or Contura
catheter. After a median followup of 40 months, the LR rate
for the ﬁrst 50 consecutive cases was 0.02% with a 3-year
actuarial rate of 2.15% [87].
The ECOG group (Eastern Cooperative Oncology
Group) prospectively studied 565 nonrandomised patients
with single areas of DCIS less than 2.5cm in size treated by
breastconservingsurgeryalone,withmarginsofgreaterthan
3mm and split these patients into a low and intermediate
group versus a high-grade group [88] attempt to determine
a sub-group of patients in whom RT could be omitted. After
a median followup of 6.7 years, the local recurrence rate was
6.1% (95% CI: 4.1–8.2%) in the low to intermediate grade
group and 15.3% (95% CI: 8.2–22.5%) in the high grade
group. On the basis of this, the authors suggest that small,
low-grade lesions excised with generous margins by breast-
conserving surgery may not need radiotherapy. The authors
did caution that longer followup and additional study would
beneededtoconﬁrmthisandraisethepointthatrecurrences
from low-grade lesions may present later.
The Radiation Therapy Oncology Group trial (98-04)
was a randomised trial designed to assess the need for
radiotherapy for DCIS in patients with “low-risk” but
unfortunately closed due to nonaccrual. A recent study
attempted to account for the nonrandomisation in the
ECOGDCISstudybycomparingtwogroupsofpatients(low
and intermediate or high grade DCIS) that were treated with
breast-conserving surgery and radiotherapy with the two
groups in the ECOG study [89]. In these 263 patients, with
similar length of followup, there was a reduction of more
than 70% in the local recurrence rates with radiotherapy.
More evidence is needed to conﬁrmif there is a subgroup
of patients with DCIS that do not need radiotherapy after
breast conservation.
3.3. Endocrine Therapy. Hormonal therapies (mainly Tam-
oxifen) are the main stay of systemic adjuvant therapy in
DCIS.
The NSABP B-24 trial was designed to assess the beneﬁt
of Tamoxifen for 5 years versus placebo after BCS and
RT for DCIS [90]. After 7 year median followup, the LR
rates were 11.1% and 8% in the placebo and Tamoxifen
groups, respectively (P = 0.02). The absolute reduction was
signiﬁcant for invasive LR. There was a signiﬁcant excess
of endometrial cancer and thromboembolic events in the
Tamoxifen group. No signiﬁcant beneﬁt was observed in
the following groups: age >50 years, in situ LR, complete
local excision, and absence of necrosis. The overall mortality
was not aﬀected [91]. A posthoc analysis of ER status
demonstrated that eﬃcacy was limited to the 77% of cases
w h i c hw e r eE Rp o s i t i v e[ 92].
The UK/ANZ DCIS trial also assessed the eﬀect of
adjuvant treatment with Tamoxifen after BCS and RT for
DCIS. The results were originally reported after a median
followup of 4.4 years [75]. At this point, there was no
signiﬁcant diﬀerence in the incidence of invasive breast can-
cer events in the Tamoxifen-treated patients. However, the
total number of DCIS events (ipsilateral and contralateral)
was signiﬁcantly reduced by Tamoxifen (6% versus 10%,
P = 0.03). After a median of 12.7 years followup [76], a
signiﬁcant diﬀerence in all new breast events in Tamoxifen
treated patients was seen (HR 0.71, 95% CI 0.58–0.88;
P = 0.002). Tamoxifen reduced both recurrent ipsilateral
DCIS ( HR 0.70, 95% CI 0.51–0.86; P = 0.03) and contralat-
eral tumours (HR 0.44, 95% CI 0.25–0.77; P = 0.005). No
signiﬁcant reduction in ipsilateral invasive disease has been
proven (HR 0.95, 95% CI 0.66–1.38; P = 0.8).
There is, therefore, good data that Tamoxifen reduces
local recurrence and the risk of contra-lateral tumours in
DCIS treated by BCS and RT. Some DCIS is probably low-
risk enough to omit it, but clear evidence on this is lacking.
There is currently only limited data on the use of
aromatase inhibitors in DCIS.
Trials are ongoing to determine if Aromatase inhibitors
are superior to Tamoxifen in the adjuvant setting after breast
conserving surgery for DCIS (NSABP B-35 and IBIS II).
Recently, inhibition of cyclo-oxygenase 2 (COX-2),
implicated in epithelial-stromal interactions and promoting
the progression of DCIS, has been evaluated using nons-
teroidal anti-inﬂammatory drugs (NSAIDS). Results fromInternational Journal of Surgical Oncology 7
experimental studies were encouraging [93, 94]b u tw e r en o t
s u p p o r t e db yt h eE R I S A Ct r i a l[ 95].
3.4.SentinelLymphNodeBiopsy. PureDCISdoesnotexhibit
lymphatic or vascular invasion so surgical staging of the
axilla is not necessary [59]. However, lesions thought to
be noninvasive on core biopsy are upgraded in 10–33% of
cases on ﬁnal postoperative histology [96, 97]a n dl y m p h
node positivity has been reported in 1-2% of patients (20)
(which may be attributable to “missed” invasive foci) [27]. A
relative indication for SLNB in DCIS is patients undergoing
Mx, as these patients are likely to have risk factors for
occult invasion—large or multifocal lesions, high-grade,
mastectomy for recurrent disease [97].
Retrospective analyses from the NSABP B-17 and B-24
trialssupportthestrategyofavoidingroutineaxillarysurgery
in DCIS due to low yield and risk of morbidity [98, 99].
3.5. Local Recurrence. If LR occurs after DCIS, it may be in
situ or invasive. It occurs at the site of the original lesion or
within the index quadrant in 75–80%. The risk decreases as
the extent of primary treatment increases (BCS, BCS+RT,
Mx). Ironically, LR can be more aggressive in those who were
treated more aggressively. Whereas 40–50% of LR is invasive
after BCS, LR is almost always invasive following Mx. This
may reﬂect the fact that recurrence after BCS often presents
as an incidental ﬁnding of in situ disease during surveillance
mammography, whereas postMx ipsilateral mammographic
screening is obviously not undertaken and recurrence is
l i k e l yt op r e s e n ta tam o r ea d v a n c e ds t a g ea n dr e l i e so n
clinical detection [100]. The prognostic implications of
invasive LR are signiﬁcantly worse than in situ recurrence.
In particular, the overall risk of metastasis has been reported
to be 0–3.6% for in situ LR, compared to 13.2–18% after
invasive LR [37, 38, 71, 72, 101]. The rate of axillary lymph
node involvement with invasive LR ranges from 11–30%
[37, 38, 71, 72].
Completion Mx is indicated following LR within the
breast when reexcision would be cosmetically unacceptable,
or when LR is conﬁrmed to be invasive and for those with
an absolute or relative contraindication to RT (i.e., previous
adjuvant RT). In the NSABP B-17 trial, the Mx rate for LR
was 48% in the BCS group and 62% in the BCS+RT group
[35], consistent with similar studies reporting rates of 52.8%
and 74.7%, respectively, [37, 38]. Overall, salvage Mx rates
range from 64–84% [37, 38, 71, 72].
3.6. Special Clinical Scenarios. Management of the elderly
DCISpatient(particularlythoseover70years)isnotstrongly
evidence based as this group has often been excluded from
important trials and screening programs [35, 45, 46, 71, 72,
90, 91].
Women exposed to thoracic radiation, including prior
treatment for haematological malignancies, are at risk of
developingsecondarytumours,withbreastcancerrepresent-
ing the most common solid lesion and DCIS accounting for
11–17.7%. The risk is signiﬁcantly increased at adolescence
and young adulthood with a median onset interval of 16
years.Inonestudy,themajorityofthesepatientsweretreated
with Mx, however, 29% underwent BCS±RT [102].
Male DCIS has been reported in approximately 300
cases, however, the incidence of DCIS within IBC ranges
from 0% to 17% with an average of 7% [103, 104].
Patients may present with a subareolar mass, Paget’s disease,
or serosanguineous nipple discharge. Optimal control is
achievedwithsimplemastectomyandlumpectomyalonehas
been associated with a higher rate of LR.
3.7. Future Strategies. Minimally invasive interventions for
breast cancer seek to redress the balance between beneﬁt
and risk and may, therefore, be of particular use in asymp-
tomatic patients with low-risk lesions or patients deemed
unﬁt for conventional management. Image-guided radiofre-
quency ablation therapy (RFA) has been demonstrated in
pilot studies to be eﬀective with few complications and a
favourable safety proﬁle. However, complete ablation may
not achievable in all patients and exhaustive histological
specimen analysis is not possible. Furthermore, current
imaging modalities are relatively imprecise at delineating the
extent of DCIS and predicting/conﬁrming complete ablation
[105].
4. Summary
DCIS should be managed within the multidisciplinary team
and management tailored to patient and tumour factors.
Local control depends upon adequate surgical clearance, and
in order to reduce the risk of LR, surgical margins of at
least 2mm should be achieved. SLNB can be considered
in patients with a high-risk of occult invasive disease.
RT following BCS signiﬁcantly reduces LR, particularly in
those at high-risk. There remains a lack of level-1 evidence
supporting the omission of adjuvant RT in selected low-risk
cases. Large, multicentric, or recurrent lesions (particularly
in cases of prior RT) should be treated by Mx and immediate
reconstruction should be discussed. Adjuvant Tamoxifen
may reduce the risk of LR in patients with hormone sensitive
disease. Further research is required to determine the role of
contemporary RT regimes and endocrine therapies. Biologi-
calproﬁlingandmolecularanalysisrepresentanopportunity
to improve our understanding of the tumour biology of
this condition and rationalise its treatment. Reliable identi-
ﬁcation of low-risk lesions could allow treatment to be less
radical or safely omitted.
5. Search Strategy andSelection Criteria
Articles were identiﬁed by searches of Medline, PubMed,
Embase, and Cochrane databases up to September 2011
using the terms: “DCIS” or “ductal carcinoma in situ”a n d
“treatment” or “management” or “surgery” or “radiother-
apy” or “radiation” or “mastectomy” or “sentinel lymph
node biopsy” or “natural history” or “Tamoxifen” or “recur-
rence” or “invasive.” Studies identiﬁed were screened for
those that focused on DCIS treatment. All randomized
controlled trials and large retrospective series were included.8 International Journal of Surgical Oncology
The references in this review were selected to provide a
balanced and representative overview of a complex subject
with an extensive base of published work.
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